Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Higashide, Tomomi; Murotani, Eiji; Saito, Yoshiaki; Ohkubo, Shinji; Sugiyama, Kazuhisa

doi:10.1007/s00417-011-1865-8

Cited by 27 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…85 Intraocular injection of bevacizumab has been reported to cause rapid regression of anterior segment neovascularization in the eyes with neovascular glaucoma. 4,86 In the subset of patients that neovascular glaucoma was secondary to ocular ischemic syndrome, intraocular injection of bevacizumab may lead to central retinal artery occlusion. 86 Intravitreal bevacizumab injections may be associated with the development of secondary RRD in patients of Eales' disease within 7 days of injection.…”

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

“…4,86 In the subset of patients that neovascular glaucoma was secondary to ocular ischemic syndrome, intraocular injection of bevacizumab may lead to central retinal artery occlusion. 86 Intravitreal bevacizumab injections may be associated with the development of secondary RRD in patients of Eales' disease within 7 days of injection. 87 …”

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

See 1 more Smart Citation

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

736

505

View full text Add to dashboard Cite

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

show abstract

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

736

505

View full text Add to dashboard Cite

show abstract

“…Çalışmamıza dahil olan hiçbir olguda sistemik yan etki izlenmedi. İntravitreal enjeksiyon sonrası santral retina arter tıkanıklığı bildirilmiş olmakla birlikte bizim hiçbir olguda bu tür komplikasyon izlenmedi (29). Çalışmamızda kontrol grubu- Sonuç olarak bu çalışmayla kliniğimizde yapılan intravitreal enjeksiyonların en sık nedeni diyabetik maküla ödemi ve bu enjeksiyonlarda en sık kullanı-lan etken maddenin bevacizumab olduğu saptandı.…”

Section: Discussionunclassified

Intravitreal injections and complications

Demir¹,

Akarsu²,

Güven³

et al. 2015

Sisli Etfal

View full text Add to dashboard Cite

Amaç: Yapılan intravitreal enjeksiyonların nedenlerini, kullanılan intravitreal ilaçları ve onların komplikasyon oranlarını sunmak Gereç ve Yöntem: Beş yıllık süre diliminde intravitreal enjeksiyon yapılan hastaların kartları geriye dönük olarak incelendi. İntravitreal enjeksiyonların hangi sebeplerle yapıldığı, hangi etken maddenin verildiği, hastaların yaşı, cinsiyeti ve enjeksiyonların komplikasyonları değerlendirildi. İntravitreal enjeksiyonlar ameliyathane şartlarında topikal anestezi altında %5 povidon iyodin konjonktival alana damlatılıp serum fizyolojikle yıkandıktan sonra 27 Gauge (G) iğne ile üst temporal alanda pars planadan vitreus boşluğuna girilerek yapıldı. Bütün enjeksiyonlardan sonra 4x1 dozunda %0.3 ofloksasin damla 1 hafta boyunca kullanıldı. İntravitreal enjeksiyonlarda bevacizumab 1.25-2.5 mg, ranibizumab 0.5 mg, triamsinolon asetonid yalnız kullanıldığında 4 mg ve bevacizumab ile birlikte kullanıldığında 2 mg dozunda kullanıldı. Bulgular: Bu çalışmaya 962 hasta (514 bayan, 448 erkek) alındı. Yaş ortalaması 65±20.3 (18-89) idi. Diyabetik maküla ödemi (DMÖ) için 574 hasta, yaşa bağlı koroid neovaskularizasyonu için 143 hasta, retinal ven kök tıkanıklığı için 47 hasta, retinal ven dal tıkanıklığı için 107 hasta, proliferatif diyabetik retinopati (DR) yalnız veya eşlik eden intraoküler hemoraji için 83 hasta, santral seröz koroidopati için 5 hasta ve yetişkin viteliform dejenerasyonu için 3 hasta olmak üzere toplam 962 hasta intravitreal enjeksiyon tedavisi almıştı. Beş yıllık süre zarfında 962 hastaya 4318 intravitreal injeksiyon yapılmıştı. İntravitreal enjeksiyon'da kullanılan etken maddelerin isimleri ve kullanılma oranları şöyleydi; bevacizumab (%57), ranibizumab (%17), triamsinolon asetonid (%16) ve triamsinolon asetonid+bevacizumab (%10). Sonuçlar: En sık enjeksiyon nedeni DMÖ ve en sık kullanılan etken madde bevacizumab idi. Gelişen en ciddi komplikasyon endoftalmi olup 2 olguda gelişti. Endoftalmi oranı % 0.046 idi. Bir olguda kendiliğinden açılan vitreus içi hemoraji oluştu. Psödoendoftalmi bir olguda triamsinolon enjeksiyonu sonrasında gelişti. Retina dekolmanı izlenmedi. Anahtar kelimeler: Bevacizumab, endoftalmi, intravitreal enjeksiyon, maküla, ranibizumab, triamsinolon asetonid ABSTRACT: Intravitreal injections and complicationsObjective: To report the indications of intravitreal injections, intravitreal drugs used and their complications rate Material and Method: The charts of patients who received intravitreal injection/s for 5 years period were reviewed retrospectively. Indications for intravitreal injections, which drug was used to intravitreally, age and gender of patients, and complications of intravitreal injections were evaluated. All intravitreal injections were performed under topical anesthesia with instillation of 5% povidone iodine and irrigation with saline solution at upper temporal area through the pars plana using 27 gauge needle in the operating room. Ofloxacin 0.3% drop was used 4x1 in all cases for one week. The amount and generic name of drugs used in intravi...

show abstract

“…Moreover, Bevacizumab is beneficial in trabeculectomy augmented by Mitomycin C and improves the success rate of aqueous shunts [16,17]. The procedure is relatively safe, despite occasional reports of glaucoma, cataract and central retinal artery occlusion [18,19]. Further hazards of anti-VEGF treatment include hyphema and long term IOP elevation with serial injections [20].…”

Section: Anti-vegf Therapymentioning

confidence: 99%

A paradigm shift in the management of neovascular glaucoma

Jeganathan¹,

Wardrop²

2016

New Front Ophthalmol

View full text Add to dashboard Cite

Neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR) is a potentially devastating condition. The commonest cause of treatment failure in NVG is underlying systemic disease progression. The underlying ischemia is often refractory to medical treatment. Surgical options have evolved to include Bevacizumab in the Ophthalmologist's armamentarium. Visual prognosis can be guarded in these patients who additionally have reduced life expectancy. Thus, early diagnosis and aggressive treatment is imperative to avert visual loss, and improve their prognosis. We present a case of NVG secondary to PDR which was challenging to treat. The patient adherent to his treatment plan and achieved unusually successful results, maintaining good vision.

show abstract

Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Cited by 27 publications

References 29 publications

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Intravitreal injections and complications

A paradigm shift in the management of neovascular glaucoma

Contact Info

Product

Resources

About